Concepedia

376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

Shanu Modi, William Jacot, Hiroji Iwata, Y.H. Park, Wei Li, Junji Tsurutani, Khalil Zaman, Naoto T. Ueno, Aleix Prat, Konstantinos Papazisis,

Annals of Oncology · 2023 · 37 citations · 2 references

DOIFull text

Open access

Concepts

References

2

377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03

S.A. Hurvitz, Shanu Modi, Wěi Li et al. · Annals of Oncology · 2023 · 58 citations · Full text

, , +15

376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

Shanu Modi, William Jacot, Hiroji Iwata et al. · Annals of Oncology · 2023 · 37 citations · Full text

, , +17